What’s Going On With SoFi Technologies Stock?

SoFi Technologies, Inc. (NASDAQ: SOFI) shares are trading higher Tuesday. The company reported better-than-expected third-quarter financial results on Monday.

SoFi Technologies, Inc. (NASDAQ:SOFI) shares are trading higher Tuesday. The company reported better-than-expected third-quarter financial results on Monday. Here’s a look at what’s going on:

What To Know:

SoFi Technologies reported quarterly losses of 3 cents per share, beating the analyst consensus estimate of a loss of 7 cents per share by 57%. The company reported quarterly sales of $530.72 million, beating the analyst consensus estimate of $512.47 million by 3.56% and representing a 26.59% increase over sales of $419.26 million from the same period last year.

SoFi Technologies also raised its fiscal year 2023 adjusted net revenue guidance to between $2.045 and $2.065 billion, compared to estimates of $2.02 billion. 

On Monday, Cathie Wood-led Ark Invest purchased 473,225 shares of SoFi Technologies through Ark Fintech Innovation ETF (NYSE:ARKF). The transaction was valued at $3.3 million, based on the stock’s closing price of $6.94 on the day.

On Tuesday, Morgan Stanley analyst Jeffrey Adelson upgraded SoFi Technologies from Underweight to Equal-Weight and announced a $7 price target.

Related News: What’s Going On With Spirit Airlines Stock? 

SOFI Price Action: According to Benzinga Pro, SoFi Technologies shares are up 6.41% at $7.39 at the time of publication.

Image: Gerd Altmann from Pixabay

Total
0
Shares
Related Posts
Read More

Aldeyra Therapeutics Says That The FDA Stated That Reproxalap For Signs And Symptoms Of Dry Eye Disease Does Not Appear To Have Data To Support The Clinical Relevance Of The Ocular Signs To Support The Dry Eye Indication – 8K

https://www.sec.gov/ix?doc=/Archives/edgar/data/1341235/000119312523256532/d760002d8k.htm In subsequent communications between Aldeyra and the FDA, Aldeyra has submitted responses to the FDA that Aldeyra believes to be

ALDX